Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective.
Economic analysis helps payers assess value of tislelizumab treatment in advanced esophageal cancer, informing coverage decisions.
This economic modelling study estimates the value-based price threshold for tislelizumab plus chemotherapy in advanced oesophageal squamous cell carcinoma from the US payer perspective, adding to the evidence base for formulary decision-making. While the analysis is technically sound, economic modelling studies are inherently sensitive to input assumptions and do not contribute primary clinical evidence.
What the study was
- Study design
- Health economic modelling (Markov cost-effectiveness model)
- Population
- Advanced oesophageal squamous cell carcinoma (US payer perspective)
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- BMJ Open
Why it surfaced
Health economic modelling study; no primary clinical evidence. Low watchlist relevance. Included for completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.